Project Grant R42CA290912
Award Date
5/20/24
Completion Date
4/30/25
Dollars Obligated
$735K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Boston, MA 02134, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding to Aperture Bio, Inc., a woman-owned small business located in Boston, Massachusetts, to determine the feasibility of using Aperture Bio's platform for preclinical applications in drug development, cell therapy manufacturing, regenerative medicine, and cancer research. The $404,994 award, active from March 1, 2025 to February 28, 2026, will support Aperture Bio in assessing...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The funding will support the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are challenging to analyze using current sequencing-by-synthesis technology. This capability will enable improved cancer...
This $417,586 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will enable the Broad Institute of MIT and Harvard to develop a robust, multi-modal spatial genomics platform for profiling human tumors. The key products and services to be delivered under this 3-year project include: Extending the Institute's proprietary "Slide-Tags" technology to measure not only gene expression, but also epigenetic states and genomic variations...
The National Cancer Institute awarded a $240,092 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Scripps Research Institute in La Jolla, California. The purpose of this grant is to implement a new mass spectrometry-based protein footprinting technique called Covalent Protein Painting (CPP) to measure protein conformations in single cancer cells. The researchers aim to quantify lysine site accessibility in single cells using CPP-SCP (CPP for single cell proteomes) and...
The National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a $407,113 Project Grant under the Cancer Biology Research (CFDA 93.396) program to Trustees of Boston University. The award, effective from September 1, 2024 to August 31, 2027, supports the development of a new bio-orthogonal mid-infrared photothermal (MIP) imaging technology to quantitatively measure molecular events in cancer cells at the subcellular level. Key objectives include building a library of...
The federal Project Grant award of $703,540.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development and optimization of an implantable microdevice technology to predict the optimal therapy for individual cancer patients with head and neck cancer. The award, with a start date of December 13, 2024 and end date of November 30, 2029, involves an academic-industrial collaboration between Brigham & Women's Hospital Inc. and industry...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $169,932 to The Trustees of Columbia University in the City of New York to advance proteomics technologies for cancer research. The grant aims to enhance the capabilities of the university's Proteomics and Macromolecular Crystallography Shared Resource (PMCSR) by introducing innovative methodologies such as automated deep proteomic profiling, immunopeptidomics, and cell surfaceome...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The grant will fund the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of NSCLC subtypes. The project aims to validate the performance of this new assay for detection of minimal...
This $400,000 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a new "MCAM-96" computational microscope platform by Ramona Optics Inc., a small disadvantaged business. The MCAM-96 is designed to enable parallelized, high-throughput 3D imaging of tumor organoids at speeds 50x faster than current microscopes. The system will also capture parallelized live-cell video assays to analyze dynamic...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...